$SER
Serina Therapeutics Inc Stock $ser

$ser Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019248 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$51.00K	$5.000K	$56.00K
YoY Change	466.67%	-50.0%	600.0%
Cost Of Revenue			$1.000K
YoY Change			0.0%
Gross Profit			$55.00K
YoY Change			685.71%
Gross Profit Margin			98.21%
Selling, General & Admin	$2.323M	$1.220M	$3.433M
YoY Change	34.28%	-38.79%	117.14%
% of Gross Profit			6241.82%
Research & Development	$1.594M	$1.106M	$149.0K
YoY Change	896.25%	535.63%	-14.86%
% of Gross Profit			270.91%
Depreciation & Amortization	$24.00K	$23.00K	$31.00K
YoY Change	-25.0%	-30.3%	-6.06%
% of Gross Profit			56.36%
Operating Expenses	$3.917M	$2.326M	$3.615M
YoY Change	107.25%	7.34%	102.07%
Operating Profit	-$3.866M	-$2.321M	-$3.560M
YoY Change	104.98%	7.55%	99.78%
Interest Expense	$9.052M	$99.00K	$28.00K
YoY Change	1042.93%	-91.0%	-102.86%
% of Operating Profit
Other Income/Expense, Net	$9.043M	-$7.116M	$1.000K
YoY Change	-1240.35%	531.41%	-200.0%
Pretax Income	$5.177M	-$9.437M	-$3.458M
YoY Change	-293.24%	187.28%	25.24%
Income Tax
% Of Pretax Income
Net Earnings	$5.204M	-$9.437M	-$3.456M
YoY Change	-294.98%	187.98%	27.86%
Net Earnings / Revenue	10203.92%	-188740.0%	-6171.43%
Basic Earnings Per Share	$0.61	-$3.38
Diluted Earnings Per Share	$0.51	-$3.38	-$3.20
COMMON SHARES
Basic Shares Outstanding	8.414M shares	2.501M shares	37.95M shares
Diluted Shares Outstanding	10.16K shares	2.790M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.064M	$8.706M	$345.0K
YoY Change	2223.37%	3009.29%	-46.51%
Cash & Equivalents	$6.064M	$8.706M	$345.0K
Short-Term Investments
Other Short-Term Assets	$2.000K	$166.0K	$352.0K
YoY Change	-99.82%	-88.64%	-80.49%
Inventory
Prepaid Expenses
Receivables		$65.00K	$57.00K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$8.917M	$8.937M	$754.0K
YoY Change	560.52%	411.56%	-69.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$540.0K	$564.0K	$573.0K
YoY Change
Goodwill
YoY Change
Intangibles	$541.0K	$574.0K	$607.0K
YoY Change	-19.61%	-18.58%	-17.75%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$1.791M	$1.919M	$11.21M
YoY Change	-83.61%	-82.21%	1322.72%
TOTAL ASSETS
Total Short-Term Assets	$8.917M	$8.937M	$754.0K
Total Long-Term Assets	$1.791M	$1.919M	$11.21M
Total Assets	$10.71M	$10.86M	$11.97M
YoY Change	-12.78%	-13.37%	269.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.203M	$2.605M	$1.413M
YoY Change	137.75%	268.46%	148.77%
Accrued Expenses	$320.0K	$1.297M	$529.0K
YoY Change	25.0%	261.28%	93.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.46M	$9.770M	$3.672M
YoY Change	-54.43%	-51.25%	-51.97%
Total Short-Term Liabilities	$12.63M	$14.06M	$5.914M
YoY Change	-48.45%	-37.58%	-41.32%
LONG-TERM LIABILITIES
Long-Term Debt	$693.0K	$693.0K	$693.0K
YoY Change	-93.12%	-93.08%	-93.39%
Other Long-Term Liabilities	$13.78M	$413.0K
YoY Change
Total Long-Term Liabilities	$14.47M	$1.106M	$693.0K
YoY Change	43.7%	-88.95%	-93.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.63M	$14.06M	$5.914M
Total Long-Term Liabilities	$14.47M	$1.106M	$693.0K
Total Liabilities	$27.10M	$15.17M	$6.607M
YoY Change	-21.61%	-53.39%	-67.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$23.19M	-$5.435M	-$131.0M
YoY Change	-81.03%	-95.45%	12.74%
Common Stock	$1.000K	$1.000K	$0.00
YoY Change	-75.0%	-75.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.36M	-$4.309M	$5.469M
YoY Change
Total Liabilities & Shareholders Equity	$10.71M	$10.86M	$11.97M
YoY Change	-12.78%	-13.37%	269.18%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$5.204M	-$9.437M	-$3.456M
YoY Change	-294.98%	187.98%	27.86%
Depreciation, Depletion And Amortization	$24.00K	$23.00K	$31.00K
YoY Change	-25.0%	-30.3%	-6.06%
Cash From Operating Activities	-$8.009M	-$1.600M	-$2.050M
YoY Change	296.68%	-14.21%	55.19%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$14.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	$0.00	-$14.00K	$0.00
YoY Change		-99.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.367M	$2.728M	2.000M
YoY Change	168.35%	-76.28%	33.33%
NET CHANGE
Cash From Operating Activities	-8.009M	-$1.600M	-2.050M
Cash From Investing Activities	0.000	-$14.00K	0.000
Cash From Financing Activities	5.367M	$2.728M	2.000M
Net Change In Cash	-2.642M	$1.137M	-50.00K
YoY Change	13805.26%	-411.51%	-127.93%
FREE CASH FLOW
Cash From Operating Activities	-$8.009M	-$1.600M	-$2.050M
Capital Expenditures	$0.00	$14.00K
Free Cash Flow	-$8.009M	-$1.614M
YoY Change		-13.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
CY2024Q1	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2023Q1	SER	Cash And Restricted Cash Acquired In Connection With Merger CashAndRestrictedCashAcquiredInConnectionWithMerger		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1		usd
CY2023Q1	SER	Merger And Issuance Of Common Stock Upon Consummation Of Merger MergerAndIssuanceOfCommonStockUponConsummationOfMerger		usd
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents		usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2024Q1	SER	Finance Lease Liability Payments Due After Year Three FinanceLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
CY2023Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
CY2024Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock		shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount		shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8706000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	65000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	166000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8937000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	564000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	627000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	104000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	574000	usd
CY2024Q1	us-gaap	Assets Assets	10856000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4013000	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	9746000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	207000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	214000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14059000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1413000	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	693000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	2983000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	413000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15165000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	36404000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8414000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8414000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2410000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2410000	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	25000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1125000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	858000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5435000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33177000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4309000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-32294000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10856000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1106000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1220000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	593000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2326000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	992000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2321000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-962000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	99000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	86000	usd
CY2023Q1	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote	2240000	usd
CY2024Q1	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	7017000	usd
CY2023Q1	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-294000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-172000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7116000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2620000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1658000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.38
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.38
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2790000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2167000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2790000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8569000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-32294000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36404000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10721000	usd
CY2024Q1	SER	Stock Issued During Period Value Cancellation Of Common Stock Upon Consummation Of Merger StockIssuedDuringPeriodValueCancellationOfCommonStockUponConsummationOfMerger	-10721000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	961000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	53000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9437000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4309000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-37778000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-37778000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1658000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1658000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-36118000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-36118000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1658000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000	usd
CY2024Q1	SER	Noncash Lease Expense NoncashLeaseExpense	45000	usd
CY2023Q1	SER	Noncash Lease Expense NoncashLeaseExpense	46000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	22000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	53000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2000	usd
CY2023Q1	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote	2240000	usd
CY2024Q1	SER	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	-7017000	usd
CY2023Q1	SER	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	294000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-172000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	644000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	235000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-163000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-86000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-55000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1577000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-709000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2400000	usd
CY2024Q1	SER	Cash And Restricted Cash Acquired In Connection With Merger CashAndRestrictedCashAcquiredInConnectionWithMerger	337000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10100000	usd
CY2024Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	13000	usd
CY2023Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	11000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2728000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10089000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1137000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9380000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7619000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	532000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8756000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9912000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2023Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	497000	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	36404000	usd
CY2024Q1	us-gaap	Notes Issued1 NotesIssued1	10721000	usd
CY2024Q1	SER	Merger And Issuance Of Common Stock Upon Consummation Of Merger MergerAndIssuanceOfCommonStockUponConsummationOfMerger	961000	usd
CY2024Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	0.97682654	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	5913277	shares
CY2024Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	0.97682654	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9400000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1600000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8700000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15000000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zpraHHaovF49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zqtJwSmevdQf">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of the Company’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zwu6Dus2m2V" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zUhgNpSxvFk2">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash equivalents. The Company maintains its cash deposits in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions and may at times hold investments at Securities Investor Protection Corporation (“SIPC”) insured broker-dealers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, the balances in these accounts may be in excess of FDIC and SIPC insured limits. At March 31, 2024 and December 31, 2023, cash and cash equivalents deposits in excess of FDIC limits were approximately $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20240331_zzI7fLmiZ5m" title="Cash, FDIC insured amount">2.6</span> million and $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_z4J5Bj2FPfQh" title="Cash, FDIC insured amount">0</span>, respectively, and investments and deposits in excess of SIPC limits were $<span id="xdx_90E_ecustom--CashExcessOfSIPCInsuredLimits_iI_pn5n6_c20240331_ztxsY1Upyek5" title="Cash, SIPC insured amount">5.4</span> and $<span id="xdx_90D_ecustom--CashExcessOfSIPCInsuredLimits_iI_pn5n6_c20231231_zA9o5wKycoki" title="Cash, SIPC insured amount">7.3</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the periods ended March 31, 2024 and 2023, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomersMember_zqCgTAC5zByk">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Company’s revenue for the periods presented are related to a single grant from U.S. Government agency. See Note 4, <i>Grant Revenues,</i> for further discussion on grant awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by the Company and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by the Company or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	2600000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2024Q1	SER	Cash Excess Of Sipc Insured Limits CashExcessOfSIPCInsuredLimits	5400000	usd
CY2023Q4	SER	Cash Excess Of Sipc Insured Limits CashExcessOfSIPCInsuredLimits	7300000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8706000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619000	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	50000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8756000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7619000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zaJf0L9hsZl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zXjM0FYeKdgl">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period condensed consolidated interim financial statements to conform to current year presentation of the <i>Accounts payable and accrued liabilities </i>amount in the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	977000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	963000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	413000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	390000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	564000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	23000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	13000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	576000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	574000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	98000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M3D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1783	pure
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	131000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	132000	usd
CY2024Q1	SER	Finite Lived Intangible Assets Amortization Expense After Year Two FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo	213000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	574000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2605000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	580000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	111000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	13000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1297000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	570000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4013000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1163000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	53980	shares
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 35.17
CY2024Q1	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	250000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.8715
CY2024Q1	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	14.8715
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2983000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2983000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1077000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-172000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	905000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	5913277	shares
CY2024Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	4918000	shares
CY2024Q1	SER	Temporary Equity Shares Issued And Outstanding TemporaryEquitySharesIssuedAndOutstanding	3438000	shares
CY2024Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	36404000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	common stock are entitled to one vote for each share
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8413889	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8413889	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2410255	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2410255	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0418	pure
CY2024Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	55000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	44000	usd
CY2024Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	497000	usd
CY2024Q1	SER	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	862000	usd
CY2023Q4	SER	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	862000	usd
CY2024Q1	SER	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	235000	usd
CY2023Q4	SER	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	196000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	627000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	666000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	207000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	214000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	413000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	461000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	620000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	675000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	163000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	163000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	59000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	53000	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	104000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	110000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	24000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M25D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y5M26D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M20D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0667	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0667	pure
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.119	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.119	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	180000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	24000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	217000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	159000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	117000	usd
CY2024Q1	SER	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	10000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	683000	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	25000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	63000	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2024Q1	SER	Lessee Operating Lease Total Obligations LesseeOperatingLeaseTotalObligations	620000	usd
CY2024Q1	SER	Finance Lease Total Obligations FinanceLeaseTotalObligations	24000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	207000	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	413000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1658000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1658000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2790000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2167000	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.38
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1658000	usd
CY2023Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	85000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9437000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1743000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2790000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2167000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2031000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	359000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	689000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3323000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2790000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8569000	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.38
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.20
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3839000	shares

Files In Submission

Name	View Source	Status
0001493152-24-019248-index-headers.html	Edgar Link	pending
0001493152-24-019248-index.html	Edgar Link	pending
0001493152-24-019248.txt	Edgar Link	pending
0001493152-24-019248-xbrl.zip	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
ser-20240331_cal.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
ser-20240331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
ser-20240331_def.xml	Edgar Link	unprocessable
ser-20240331_lab.xml	Edgar Link	unprocessable
ser-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SER
Serina Therapeutics Inc Stock $ser

2024 Q2 Form 10-Q Financial Statement

#000149315224019248 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER Serina Therapeutics Inc Stock $ser

2024 Q2 Form 10-Q Financial Statement

#000149315224019248 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER
Serina Therapeutics Inc Stock $ser